Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy

In Vivo. 1991 Nov-Dec;5(6):579-81.

Abstract

Twenty-three cancer patients with pleural and/or abdominal effusion refractory to chemotherapy were treated with intracavitary beta-interferon after drainage. The overall response rate at 30 days was 35% for the whole group of patients, 25% for those with pleural effusion, and 40% for those with ascites. In 15 patients the mean time to re-accumulation of fluid after drainage only was 8.7 days, while it approached 30.3 days after intracavitary beta-interferon. This difference was statistically significant (P less than 0.001). The treatment was well tolerated with only mild and transient pain in 3 cases.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Ascitic Fluid / etiology
  • Ascitic Fluid / therapy*
  • Female
  • Humans
  • Interferon-beta / therapeutic use*
  • Male
  • Middle Aged
  • Neoplasms / complications
  • Neoplasms / therapy*
  • Pleural Effusion, Malignant / therapy*
  • Prognosis

Substances

  • Antineoplastic Agents
  • Interferon-beta